mRNA-1273 Clinical Development Program

Jacqueline M. Miller, M.D., F.A.A.P.

August 26, 2020
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning the timing, design, objectives and other parameters of the Phase 1, Phase 2 and Phase 3 clinical studies of mRNA-1273. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no commercial product using mRNA technology has been approved, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new class of medicines; despite having ongoing interactions with the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or other regulatory agencies, the FDA, EMA or such other regulatory agencies may not agree with Moderna's regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; potential adverse impacts due to the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.
mRNA-1273 encodes for the full-length Spike Protein in the Pre-fusion Conformation (S-2P)
Pre-clinical data support human clinical trials with mRNA-1273

- Robust neutralizing antibody responses in mice\(^1\), aged mice, and non-human primates (NHPs)\(^2\) have been induced
- mRNA-1273 demonstrated robust protection against lung challenge in mice\(^1\), and pulmonary and nasal challenge in NHPs\(^2\)
- No indication of enhanced respiratory disease after viral challenge even when subprotective doses of mRNA-1273 are used\(^2\)
- A Th1-dominant phenotype of CD4+ T-cells has induced in mice\(^1\) and NHPs\(^2\)

mRNA-1273 Clinical Development Plan

2020
- P101 First in Human and Dose-Ranging (NIH Sponsored)

2021
- P201 Phase 2 Safety and Immunogenicity Trial
- P301 Phase 3 Pivotal Safety, Efficacy, and Immunogenicity Trial
- Dose Selection for P301 Safety and immunogenicity P101 Response relative to convalescent sera
- Data Package Required Prior to Start P301 Safety & immunogenicity from P101 (post-dose 2 data for 100ug cohorts)
- P201 safety report from SMC
- Animal model data demonstrating nAbs, protection from challenge, Th-1-biased CD4+ T-cells and protection from ERD

Other populations for further evaluation (timing TBD)
- Pediatrics
- Pregnant women
- Immunocompromised populations

Study end dates are estimated

© 2020 Moderna
**mRNA-1273 NIH-Sponsored, Phase 1, Safety and Dose-Ranging Study (N=120)**

**Phase 1 trial overview (NCT04283461)**

<table>
<thead>
<tr>
<th>Protocol Title</th>
<th>Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study Groups</strong></td>
<td><strong>Cohorts</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>1-3</td>
<td>18 to 55</td>
</tr>
<tr>
<td>4, 5</td>
<td>56 to 70</td>
</tr>
<tr>
<td>7, 8</td>
<td>≥71</td>
</tr>
<tr>
<td>10-13</td>
<td>18-55, 56-70, ≥71</td>
</tr>
</tbody>
</table>

**Population**
Healthy males and females at or above 18 years of age

“All-comers” with regard to SARS-CoV-2 serostatus (baseline serology will be collected)

**Study Endpoints**
Safety (solicited AR x 7 days post each injection; unsolicited AE 28 days post-vaccination; SAE and MAAE)
Immunogenicity (e.g., ELISA, pseudoneutralization, live virus neutralization and intracellular cytokine staining assay)

**Study duration**
Approximately 13 months for each participant corresponding to a 12-month follow up after the last vaccine administration

---

1. Cohorts 6 and 9 (250 mcg cohorts) will not be enrolled on this study


© 2020 Moderna
Dose selection of 100 mcg was based on comparable nAb titers to 250 mcg with improved safety profile

Pseudovirus neutralization assay titers (ID$_{50}$): age 18 – 55 Years

Key Takeaways

- Day 14 post-dose 2, nAbs were observed in all participants
- The lowest responses were in the 25 mcg dose group
- Responses in the 100 mcg and 250 mcg groups were similar to the upper half of the range of convalescent sera


© 2020 Moderna
### Phase 1: No Vaccine-Related SAEs Have Been Reported

Solicited Local and Systemic Symptoms Followed for 7 Days Post-vaccination

Majority of symptoms resolved within 2 days, some persisted as long as 5 days

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Age group</th>
<th>Vaccination 1</th>
<th>Vaccination 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any systemic symptom</td>
<td>18-55</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56-70</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>18-55</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56-70</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>18-55</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56-70</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever 1</td>
<td>18-55</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56-70</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chills</td>
<td>18-55</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56-70</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>18-55</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56-70</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Percentage of severity

**Symptom**

1. Fever percentages reflect the number of subjects with at least one measurement available in the data system as the denominator. This denominator may differ from other systemic symptoms, which are solicited in-clinic at the post-dose assessment.
2. 18-55: N=13; 56-70: N=10; 71+: N=10; N = All subjects receiving Dose 1 with any solicited event data recorded in the database.


© 2020 Moderna
Anti-S-2P Binding Ab (ELISA) Comparable Across Age Strata and to Convalescent Sera at one month PD2

S-2P binding antibodies (ELISA)- 100 μg at Day 1 and Day 29

18 – 55 years  
56 – 70 years  
71+ years

Range of convalescent sera

Key Takeaways

- 100 mcg two-dose series seroconverted all participants PD1
- PD1 AUC for all age groups exceeded the median of convalescent sera
- PD2 all age groups is equivalent to high-titer convalescent sera (i.e., upper quartile)


Interim Immunogenicity Report

© 2020 Moderna

PD1= Post-dose 1; PD2= Post-dose 2
Vaccination administered at Day 1 and Day 29

Interim unpublished data
SARS-CoV-2 nAb Comparable Across Age Strata and to Convalescent Sera out to Day 57 PD2

Pseudovirus neutralization assay titers (ID50) - 100 μg at Day 1 and Day 29

Key Takeaways

- PD2 pseudovirus neutralization responses were detected in all participants
- PsV titers were comparable across age groups
- PsV median titer for 56-70 and 71+ YOA above convalescent sera median titer at Day 57 PD2


© 2020 Moderna
mRNA-1273 induces CD4+ T-cells of the Th-1 Phenotype 14 days PD2

Th1 CD4+ T cell response, S1 peptide pool (100 μg at Day 1 and 29)

Key Takeaways

- Vaccination with 100 mcg mRNA-1273 led a Th1-biased CD4+ T-cell response across all age groups
- Th2 phenotype was rare (data not shown)

Interim unpublished data

mRNA-1273 Phase 2 Study will Evaluate Safety and Immunogenicity of 50 mcg and 100 mcg (N=600)

Phase 2 trial overview (NCT04405076)

<table>
<thead>
<tr>
<th>Protocol Title</th>
<th>A Phase 2a, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Groups</td>
<td><strong>Cohorts</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cohort 1</td>
</tr>
<tr>
<td></td>
<td>Cohort 2 Sentinel</td>
</tr>
<tr>
<td></td>
<td>Cohort 2 Full</td>
</tr>
<tr>
<td>Participant Population</td>
<td>Healthy males and females at or above 18 years of age</td>
</tr>
<tr>
<td>Study Endpoints</td>
<td>Safety (solicited AR x 7 days post each injection; unsolicited AE to day 57; SAE and MAAE throughout the study); assessment of any cases of Covid-19; potential assessment for asymptomatic infection</td>
</tr>
<tr>
<td>Study Duration</td>
<td>Approximately 13 months for each participant corresponding to a 12-month follow up after the last vaccine administration</td>
</tr>
</tbody>
</table>
# Pivotal Phase 3 Efficacy, Safety and Immunogenicity Study (N=30,000)

## Phase 3 trial overview (NCT04470427)

<table>
<thead>
<tr>
<th>Protocol Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Groups</th>
<th>Strata</th>
<th>Dosage IM (D1, D29) 1:1</th>
<th>Sample Size</th>
<th>Enrollment status</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 65 years</td>
<td></td>
<td>100mcg, placebo</td>
<td>25-40%</td>
<td>Started July 27</td>
</tr>
<tr>
<td>&lt; 65 years at increased risk for complication of COVID-19 (&quot;at risk&quot;)</td>
<td></td>
<td>100mcg, placebo</td>
<td>Started July 27</td>
<td></td>
</tr>
<tr>
<td>&lt; 65 years and not at risk</td>
<td></td>
<td>100mcg, placebo</td>
<td>60-75%</td>
<td>Started July 27</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participant Population</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approximately 30,000 participants (case driven) whose locations or circumstances put them at appreciable risk of acquiring COVID-19 and/or SARS-CoV-2 infection</td>
<td></td>
</tr>
<tr>
<td>&quot;All-comers&quot; with regard to SARS-CoV-2 serostatus (baseline serology will be collected)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Objectives</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>To demonstrate the efficacy of mRNA 1273 to prevent COVID 19</td>
<td></td>
</tr>
<tr>
<td>To evaluate the safety and reactogenicity of 2 injections of the mRNA-1273 vaccine given 28 days apart</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Duration</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approximately 25 months for each participant corresponding to a 24-month follow up after the last vaccine administration</td>
<td></td>
</tr>
</tbody>
</table>
Primary Efficacy Endpoint: COVID-19 Disease Case Definition

To be considered a case of COVID-19 for the evaluation of the Primary Efficacy Endpoint, two criteria must be met:

1. The participant must have experienced:
   - At least **TWO** of the following systemic symptoms: fever (≥ 38°C), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s)

   **OR**

   - At least **ONE** of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, OR clinical or radiographical evidence of pneumonia

2. The participant must have at least one NP swab, nasal swab or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR

Primary analysis set is seronegative and negative NP swab at baseline without major PD (Per Protocol)
COVE D&I Advisory Committee

Remit and Role of Advisory Committee:
1. Review enrollment, race, and ethnicity demographics on a weekly basis
2. Review current outreach activities and outcomes
3. Review strategies to ensure participation of individuals from communities significantly impacted by COVID-19
4. Support the development and implementation of retention strategies

- National Institute on Allergy and Infectious Diseases
- National Institute on Minority Health and Health Disparities
- NIH, Tribal Health Research Office
- NHLBI
Limitations of Research

- Limited safety and immunogenicity data in a fairly homogeneous population
- Further evaluation needed in terms of vaccine use in:
  - Pediatric subjects
  - Pregnant women
  - Immunocompromised patients
- The ongoing COVE Study will provide significantly more data
Summary

- mRNA-1273 encodes the pre-fusion-stabilized Spike protein (S-2P) in a Lipid Nanoparticle designed for delivery to the APCs of the lymph node

- Pre-clinical data have demonstrated induction of neutralizingAbs and protection against viral challenge in mice and NHPs

- Interim data from Phase 1 study indicate that a 100 mcg dose of vaccine:
  - Is generally well-tolerated across age strata, with solicited symptoms mostly mild-to-moderate in severity and self-limited duration
  - Induces neutralizingAbs in the upper half of the range of convalescent serum across age strata, with the induction of Th-1 biased, CD4+ T-cells

- Phase 2 and the Phase 3 COVE study are underway

APC – Antigen presenting cells    NHP – Nonhuman primate
Thank you to our collaborators

P101

- Division of Microbiology and Infectious Diseases, NIAID
- Vaccine Research Center (VRC), NIAID
- Coalition for Epidemic Preparedness Innovation
- Principal Investigators, Drs. Lisa Jackson (Kaiser Permanente Washington), Evan Anderson (Emory University School of Medicine), Nadine Rouphael (Emory University School of Medicine), Alicia Widge (VRC)
- The Emmes Company
- Denison Lab, Vanderbilt University
- Baric Lab, University of North Carolina
- Suthar Lab, Emory University
- Vaccine Immunology Program, NIAID
- Study sites, investigators and subjects

P201

- BARDA
- Study sites, investigators, and subjects

COVE Study (P301)

- BARDA
- Operation Warp Speed
- NIAID and the COVID-19 Prevention Network
- Members of Diversity and Inclusion Panel
- Principal Investigators, Drs. Brandon Essink (Meridian Clinical Research), Lindsey Baden (Brigham and Women’s Hospital), Hana El Sahly (Baylor College of Medicine)
- Study sites, investigators, and subjects